[go: up one dir, main page]

PE20010217A1 - Uracilos sustituidos de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion - Google Patents

Uracilos sustituidos de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion

Info

Publication number
PE20010217A1
PE20010217A1 PE2000000543A PE0005432000A PE20010217A1 PE 20010217 A1 PE20010217 A1 PE 20010217A1 PE 2000000543 A PE2000000543 A PE 2000000543A PE 0005432000 A PE0005432000 A PE 0005432000A PE 20010217 A1 PE20010217 A1 PE 20010217A1
Authority
PE
Peru
Prior art keywords
hydride
aryls
alkyl
coagulation cascade
selective inhibition
Prior art date
Application number
PE2000000543A
Other languages
English (en)
Inventor
Michael S South
Melvin L Rueppel
Darin E Jones
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of PE20010217A1 publication Critical patent/PE20010217A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A URACILOS SUSTITUIDOS CON ARILOS Y HETEROARILOS POLICICLICOS I, DONDE: B ES EL GRUPO a; D1, D2, J1, J2, K1 SON C, N, O, S, ENLACE, NO MAS DE UNO DE D1, D2, J1, J2, K1 ES O, S, ENTRE OTRAS CONDICIONES; R9, R10, R11, R12, R13, R32, R33, R34, R35, R36 SON HIDRURO, ACETAMIDO, HALOACETAMIDO, ENTRE OTROS; R16, R19, R32, R33, R34, R35, R36 SON Qb, NO MAS DE UNO DE R16 Y R19 ES Qb; Qb ES Qbc; B ES HIDRURO, TRIALQUILSILILO, ALQUILO C2-C8, ENTRE OTROS; A ES UN ENLACE, (W7)rr-(CH(R15)pa Y (CH(R15))pa-(W7)rr; rr ES 0-1; pa ES 0-6; W7 ES O, S, C(O), (R7)NC(S), N(R7); R7 ES HIDRURO, OH, ALQUILO; R15 ES HIDRURO, OH, ES NH, NOH; M ES N, R1-C; R1 ES HIDRURO, ALQUILO, ALQUENILO, ENTRE OTROS; R2 ES Z°-Q; Z° ES (CR41R42)q, q ES 1-3, ENTRE OTROS; W° ES O, S, C(O), S(O), N(R41), ENTRE OTROS; R41 Y R42 SON AMIDINO, HIDROXIAMINO, ENTRE OTROS; Q ES HIDRURO; K ES (CR4aR4b)n, n ES 1-2; R4a Y R4b SON HALO, HIDRURO, ENTRE OTROS; E° ES E1 CUANDO K ES (CR4aR4b); E1 ES CO, C(S), CONR7, ENTRE OTROS; Y° ES Qb-Qssss, ENTRE OTROS; Qssss ES (CH(R38))r-W5; r ES 1-2; W5 ES 1,4 INDENILO; 1,5 INDENILO, ENTRE OTROS; R38 ES ARILO, HETEROARILO. UN COMPUESTO PREFERIDO 2-[3-[1-[3-AMINOFENIL]-N-[[4-IMINOMETILFENIL]METIL]-5-[N,N-DIMETILHIDRAZINA]-2,4-DIOXO-2(2H,4H)-PIRIMIDINIL]]ACETAMIDA, ENTRE OTROS. EL COMPUESTO I INHIBE LA TROMBOSIS, FORMACION DE PLAQUETAS
PE2000000543A 1999-05-19 2000-06-02 Uracilos sustituidos de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion PE20010217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13495799P 1999-05-19 1999-05-19

Publications (1)

Publication Number Publication Date
PE20010217A1 true PE20010217A1 (es) 2001-03-07

Family

ID=22465795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000543A PE20010217A1 (es) 1999-05-19 2000-06-02 Uracilos sustituidos de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion

Country Status (14)

Country Link
EP (1) EP1178971A1 (es)
JP (1) JP2002544263A (es)
KR (1) KR20010113969A (es)
CN (1) CN1152023C (es)
AR (1) AR043677A1 (es)
AU (1) AU771740B2 (es)
BR (1) BR0011273A (es)
CA (1) CA2373610A1 (es)
MX (1) MXPA01011806A (es)
NZ (1) NZ514877A (es)
PE (1) PE20010217A1 (es)
UY (1) UY26157A1 (es)
WO (1) WO2000069833A1 (es)
ZA (2) ZA200109338B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6458952B1 (en) * 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
AU2004200664B2 (en) * 2000-01-25 2007-08-16 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
JP4931314B2 (ja) 2000-01-25 2012-05-16 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプタアンタゴニストおよびそれに関連した方法
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
CA2405561A1 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
EP1268428A2 (en) 2000-04-05 2003-01-02 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
MXPA03004458A (es) 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
WO2003029216A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
AU2002367752A1 (en) 2001-10-03 2003-11-17 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
EP2785700B1 (en) 2011-11-29 2016-03-09 Perosphere, Inc. Anticoagulant reversal agents
AU2020396565C1 (en) * 2019-12-04 2025-05-15 Omeros Corporation MASP-2 inhibitors and methods of use
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509994A (pt) * 1994-12-13 1997-12-30 Corvas Int Inc Derivados heterocíclicos aromáticos como inibidores de enzimas
JP2002544262A (ja) * 1999-05-19 2002-12-24 ファルマシア・コーポレイション 有用な抗凝血剤としての置換多環式アリールおよびヘテロアリールピリミジノン

Also Published As

Publication number Publication date
CA2373610A1 (en) 2000-11-23
NZ514877A (en) 2004-10-29
EP1178971A1 (en) 2002-02-13
MXPA01011806A (es) 2003-09-04
WO2000069833A1 (en) 2000-11-23
BR0011273A (pt) 2002-06-18
AU771740B2 (en) 2004-04-01
ZA200400450B (en) 2004-09-29
JP2002544263A (ja) 2002-12-24
ZA200109338B (en) 2004-05-26
AU4972400A (en) 2000-12-05
CN1351594A (zh) 2002-05-29
KR20010113969A (ko) 2001-12-28
UY26157A1 (es) 2000-12-29
CN1152023C (zh) 2004-06-02
AR043677A1 (es) 2005-08-10

Similar Documents

Publication Publication Date Title
PE20010217A1 (es) Uracilos sustituidos de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion
PE20010290A1 (es) Pirazinonas sustituidas de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion
PE20010229A1 (es) Pirimidonas sustituidas de arilos y heteroarilos policiclicos utiles para la inhibicion selectiva de la cascada de coagulacion
CO5680407A2 (es) Inhibidores novedosos de cinasas
PE20000762A1 (es) Inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
PE20020544A1 (es) Derivados de indolilmaleimida
ZA969273B (en) Inhibitors of protein isoprenyl transferases.
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
TW200510431A (en) Quinazoline derivatives
ATE445400T1 (de) Hydantion-derivate als hemmer von matrix- metalloproteinasen
NZ509939A (en) 1H-imidazopyridine derivatives useful as TNF or IL-1 inhibitors
TR200201752T2 (tr) Dipeptid nitril katepsin K inhibitörleri.
TR200002606T2 (tr) Benzen-sülfonamit türevleri ve ilaç olarak kullanımları.
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
NO308466B1 (no) Urea- og amidderivater og deres anvendelser i kontroll av kaliumkanaler i cellemembranen
ATE524522T1 (de) Xanthen-farbstoffe
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
HRP950482B1 (en) SYNTHESIS OF 3-(4-(2-AMINOETOXY)BENZOYL)-ARYL-6-HYDROXYBENZO(b)THIOPHENE
HRP20030126B1 (en) Selective cyclic peptides
NO20004871D0 (no) Benzamid- og sulfonamid-substituert aminoguanidiner og alkoksyguanidiner som protease inhibitorer
PE20000942A1 (es) Derivados de amida, carbamato y urea
MXPA05007671A (es) Derivados de triazina como absorbedores de uv.
DE60128683D1 (de) Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
MY130411A (en) Piperidine derivatives

Legal Events

Date Code Title Description
FC Refusal